Related Experiment Video
Updated: Apr 7, 2026
08:37
Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer
Published on: November 15, 2024
854
Semaglutide and Alcohol use Disorder: Breaking Free of Addiction?
Georgios S Papaetis1,2, Michalis K Picolos3,4
1K.M.P THERAPIS Paphos Medical Center, Internal Medicine and Diabetes Clinic, 14 Vasileos Georgiou B Street, Office 201, 8010, Paphos, Cyprus.
Current Pharmaceutical Design
|April 6, 2026
Summary
Glucagon-like peptide-1 receptor agonists show promise for treating alcohol use disorder (AUD). This research reviews evidence for semaglutide, a GLP-1R agonist, as a novel therapeutic for AUD.
Area of Science:
- Neuroscience
- Pharmacology
- Addiction Medicine
Background:
- Alcohol use disorder (AUD) is a chronic relapsing condition with limited effective treatments.
- Current FDA-approved medications for AUD have high relapse rates.
- Novel therapeutic strategies are crucial for improving AUD treatment outcomes.
Purpose of the Study:
- To review the current treatment landscape for AUD.
- To explore the pathophysiological rationale for using GLP-1 receptor (GLP-1R) agonists in AUD.
- To examine preclinical and clinical evidence for semaglutide in AUD treatment.
Main Methods:
- Literature review of preclinical and clinical studies on GLP-1R agonists and AUD.
- Analysis of the role of GLP-1 pathways in reward systems.
- Evaluation of semaglutide's efficacy and safety data for AUD.
Main Results:
- GLP-1 receptors are present in brain regions regulating reward.
- Preclinical studies suggest GLP-1R agonists reduce alcohol intake.
- Clinical evidence on semaglutide for AUD is emerging and promising.
Conclusions:
- GLP-1R agonists represent a novel therapeutic avenue for AUD.
- Semaglutide shows potential as an effective treatment for alcohol use disorder.
- Further research is warranted to establish semaglutide's role in AUD management.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
653
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
653
01:27CNS Depressants: Alcohol and Nicotine
1.6K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.6K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
898
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
898
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
698
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
698
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
888
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
888